RANITIDINE TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
18-09-2019
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
RANITIDINE (RANITIDINE HYDROCHLORIDE)
から入手可能:
PRO DOC LIMITEE
ATCコード:
A02BA02
INN（国際名）:
RANITIDINE
投薬量:
300MG
医薬品形態:
TABLET
構図:
RANITIDINE (RANITIDINE HYDROCHLORIDE) 300MG
投与経路:
ORAL
パッケージ内のユニット:
100/30
処方タイプ:
Prescription
治療領域:
HISTAMINE H2-ANTAGONISTS
製品概要:
Active ingredient group (AIG) number: 0115150001; AHFS:
認証ステータス:
CANCELLED POST MARKET
承認日:
2023-07-10
製品の特徴
_ _
RANITIDINE_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR RANITIDINE
Ranitidine Tablets, USP
150 mg & 300 mg ranitidine (as ranitidine hydrochloride)
Histamine H
2
-receptor antagonist
PRO DOC LTÉE
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Date of Revision:
September 18, 2019
Submission Control No: 229390
RANITIDINE_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
................................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
CLINICAL TRIALS
..........................................................................................................14
DETAILED PHARMACOLOGY
................
完全なドキュメントを読む
